Effects of Dexmedetomidine on Clinical Outcomes and Renal Function after CABG

Background: this study was carried out to determine the effects of dexmedetomidine on clinical outcomes and renal function after coronary artery bypass grafting (cabg) to address the increased rate of cabg? and the importance of modification in stress responses and control of adverse effects on renal function and with the aim of cost reduction.materials and methods: this double-blind randomized clinical trial was carried out with the participation of 129 subjects under elective cabg in rajaei heart center, tehran, iran in 2017. patients were randomly assigned to four groups with simple randomization including one placebo (normal saline infusion) group and three dexmedetomidine groups; 0.5 μg/kg/h on cpb, 0.5 μg/kg/h in 24 hours, and 0.75 μg/kg/h in 24 hours. the blood pressure, blood urea nitrogen (bun), serum creatinine, transfused blood volume, urine volume, and hemofiltration on pump and lactate were assessed at different time intervals.results: results showed more stability especially in central venous pressure (cvp) (p=0.001) and systolic blood pressure (p=0.006) in the groups receiving dexmedetomidine 0.75 μg/kg/h per 24 hours. but diastolic blood pressure and heart rate were the same across the groups (p>0.05). all other variables including hepatic and renal function tests were the same across the groups (p>0.05).conclusion: overall, according to the obtained results in the current study, it may be concluded that dexmedetomidine would have some promising effects on hemodynamic stability but there are no obvious renoprotective effects for this medication.